Delcath Systems (DCTH) Is a Great Choice for 'Trend' Investors, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Delcath Systems (DCTH) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Here's Why Delcath Systems, Inc. (DCTH) is a Great Momentum Stock to Buy
Does Delcath Systems, Inc. (DCTH) have what it takes to be a top stock pick for momentum investors? Let's find out.
Does Delcath Systems (DCTH) Have the Potential to Rally 42.77% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 42.8% in Delcath Systems (DCTH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Delcath Systems, Inc. (DCTH) Q2 2026 Earnings Call Transcript
Delcath Systems, Inc. (DCTH) Q2 2026 Earnings Call Transcript
Delcath Systems Q2 Earnings Call Highlights
Delcath Systems NASDAQ: DCTH reported second-quarter 2026 revenue of $29.1 million, up from $24.2 million a year earlier, as growth in HEPZATO KIT sales supported continued commercial expansion and investment in clinical programs beyond metastatic uveal melanoma.
Delcath Systems, Inc. (DCTH) Tops Q2 Earnings and Revenue Estimates
Delcath Systems, Inc. (DCTH) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.16 per share. This compares to earnings of $0.07 per share a year ago.
Delcath Systems, Inc. (DCTH) Q1 2026 Earnings Call Transcript
Delcath Systems, Inc. (DCTH) Q1 2026 Earnings Call Transcript
Delcath Systems, Inc. (DCTH) Reports Q1 Loss, Misses Revenue Estimates
Delcath Systems, Inc. (DCTH) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to earnings of $0.03 per share a year ago.
Delcath: Fundamentals Intact, Despite Share Price Weakness
Delcath Systems, Inc.'s revenue remains under pressure due to weak patient starts in the third quarter of 2025. The fundamentals of the company remain intact, though, and 2026 should be another year of strong growth. Delcath's profitability will be under pressure due to investments in clinical trials and sales and marketing.
Delcath Systems: Stabilizing Fundamentals Justify A Rating Upgrade
Delcath Systems is upgraded from Hold to Buy as sales stabilize and insider confidence grows. DCTH expects to hit the upper end of 2025 guidance at $85M, signaling operational stabilization after earlier guidance cuts. CHOPIN trial results expand HEPZATO's potential beyond liver therapies, supporting a broader market opportunity.
Delcath: Temporary Headwinds Are No Cause For Concern
Delcath's third quarter was weak due to seasonality and pricing headwinds, but data suggests these are temporary challenges. Delcath continues to expand its treatment sites and sales force, which should lead to strong growth in 2026. Clinical trials to expand the company's addressable market are also now under way, which could provide enormous upside in several years time.
Delcath Systems, Inc. (DCTH) Q3 2025 Earnings Call Transcript
Delcath Systems, Inc. ( DCTH ) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants David Hoffman - General Counsel, Corporate Secretary & Chief Compliance Officer Gerard Michel - CEO & Director Sandra Pennell - Chief Financial Officer Vojislav Vukovic - Chief Medical Officer Conference Call Participants Marie Thibault - BTIG, LLC, Research Division John Newman - Canaccord Genuity Corp., Research Division Jake Soucheray Kesav Chandrasekhar Swayampakula Ramakanth - H.C. Wainwright & Co, LLC, Research Division Yale Jen Bill Maughan Presentation Operator ” David Hoffman General Counsel, Corporate Secretary & Chief Compliance Officer ” Gerard Michel CEO & Director ” Sandra Pennell Chief Financial Officer ” Vojislav Vukovic Chief Medical Officer ” Marie Thibault BTIG, LLC, Research Division ” BTIG, LLC, Research Division John Newman Canaccord Genuity Corp., Research Division ” Canaccord Genuity Corp., Research Division Jake Soucheray ” Craig-Hallum Capital Group LLC, Research Division Kesav Chandrasekhar ” Stephens Inc., Research Division Swayampakula Ramakanth H.C.
